We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Spaeth/Richman Contrast Sensitivity Test (SPARCS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01300949
First Posted: February 23, 2011
Last Update Posted: January 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Pfizer
Information provided by (Responsible Party):
George L. Spaeth MD, Wills Eye
  Purpose
The Spaeth-Richman Contrast Sensitivity (SPARCS) test is a new method of assessing contrast sensitivity. The test is performed on any standard computer with internet access. Patients will be tested with SPARCS and with the standard Pelli-Robson contrast test.

Condition
Glaucoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Validation and Reproducibility of Spaeth/Richman Contrast Sensitivity Test

Resource links provided by NLM:


Further study details as provided by George L. Spaeth MD, Wills Eye:

Primary Outcome Measures:
  • Contrast Sensitivity [ Time Frame: 1 day ]
    If this instrument is a user-friendly, highly specific and sensitive method of determining contrast sensitivity, without influence of acuity, a major advance will be made. It is conceivable that the test could be used for detection of visual disease globally because of ease of operation and availability. Increasing numbers of studies are showing that contrast sensitivity is highly related to patients' ability to perform activities of daily living. It is anticipated that using this technique may become the standard way of assessing visual ability.


Enrollment: 315
Study Start Date: January 2010
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Objective: To test a new method of determining contrast sensitivity that does not require visual acuity and tests various areas of the visual field.

Hypothesis: A method of determining contrast sensitivity that does not require letter recognition (as in the Pelli-Robson test) eliminates the confounders of literacy and pattern recognition, and will permit a more valid determination of contrast sensitivity.

Patients will perform SPARCS and Pelli-Robson twice; once each with two separate observers for reproducibility and intra-observer reliability. The order of testing will be randomized to SPARCS, Pelli, Pelli, SPARCS or Pelli, SPARCS, SPARCS, Pelli.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Glaucoma Service, Wills Eye Institute Cataract and Primary Care Service, Wills Eye Institute Retina Service, Wills Eye Institute
Criteria

Inclusion Criteria:

  • 18 yrs of age and older
  • able to provide fully informed consent

    70 controls (patients with no ocular disease affecting visual acuity or visual function), 10 from each decade of life: 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80+.

    105 patients with ocular hypertension or any type of glaucoma (15 subjects per age decade). Glaucoma patients will not have macular degeneration or visual acuity affected by any function other than glaucoma.

    40 patients with macular degeneration: 10 with visual acuity 20/40 or better, 10 with visual acuity between 20/40 and 20/60, 10between 20/100 and 20/400, and 10 with 20/400 or worse.

    40 patients with cataracts: 10 with lens opacity 1+nuclear sclerosis, 10 with 2 + nuclear sclerosis, 10 with 3 + nuclear sclerosis, 10 with 4 + nuclear sclerosis.

    60 patients with refractive error: 10 with myopia -5 diopters or greater, 10 with myopia between -5 and -2.5, 10 with myopia between -2.5 and -0.5, 10 with myopia between -0.5 and 0.5, 10 with myopia between 0.5 and 2.5, and 10 with myopia > 2.5.

Exclusion Criteria:

  • any other diseases affecting visual acuity
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01300949


Locations
United States, Pennsylvania
Wills Eye Institute
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Wills Eye
Pfizer
Investigators
Principal Investigator: George L Spaeth, MD Glaucoma Service, Wills Eye Institute
  More Information